// App-Quantinova.ai

CT213 : Impact of smoking on outcomes with durvalumab following chemoradiotherapy in unresectable Stage III NSCLC (PACIFIC)

Researchers

Presenter

  • David Planchard

Principal Investigators

  • Mustafa zgroglu

  • Davey Daniel

  • Augusto Villegas

  • David Vicente

  • Shuji Murakami

  • Rina Hui

  • Corinne Faivre-Finn

  • Luis Paz-Ares

  • Yi-Long Wu

  • Euan Macpherson

  • Michael Newton

  • Phillip Dennis

  • Scott J. Antonia

Medical Centers

  • Gustave Roussy, Department of Medical Oncology, Thoracic Group, Villejuif, France

  • Istanbul University − Cerrahpaşa, Cerrahpaşa School of Medicine, Cerrahpaşa, Turkey

  • Tennessee Oncology, Chattanooga, TN, and Sarah Cannon Research Institute, Nashville, TN

  • Cancer Specialists of North Florida, Jacksonville, FL

  • Department of Clinical Oncology, H.U.V. Macarena, Seville, Spain

  • Kanagawa Cancer Center, Yokohama, Japan

  • Westmead Hospital and University of Sydney, Sydney, Australia

  • University of Manchester and The Christie NHS FT, Manchester, United Kingdom

  • Hospital Universitario 12 de Octubre, Lung Cancer Unit CNIO-H12o, CiberOnc and Universidad Complutense, Madrid, Spain

  • Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH) and Guangdong Academy of Medical Sciences, Guangzhou, China

  • AstraZeneca, Macclesfield, United Kingdom

  • AstraZeneca, Gaithersburg, MD

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

Locations

  • France

  • Turkey

  • United States

  • Spain

  • Japan

  • Australia

  • United Kingdom

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • N/A

Drug/Treatment

  • Durvalumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved